LBF20207PG24
LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
IDs and Links | |
---|---|
LipidBank | XPR1411 |
LipidMaps | LMFA03010030 |
CAS | |
KEGG | {{{KEGG}}} |
KNApSAcK | {{{KNApSAcK}}} |
mol | LBF20207PG24 |
15-keto Prostaglandin E2 | |
---|---|
Structural Information | |
7- [3R -Hydroxy-2R - (3-oxo-trans-1-octenyl) -5-oxocyclopentan-1R -yl] -cis-5-heptenoic acid | |
| |
15-KETO-PGE2 | |
Formula | C20H30O5 |
Exact Mass | 350.20932407 |
Average Mass | 350.4492 |
SMILES | C(CCC(=O)C=C[C@H]([C@H]1CC=CCCCC(O)=O)[C@@H](CC1=O)O)CC |
Physicochemical Information | |
15-Keto-prostaglandin E2 is the oxidized product of prostaglandin E2 by 15-hydroxyprostaglandin dehydrogenase, which is present in lung, kidney, placenta and other tissues and catalyzes the NAD- or NADP-dependent dehydrogenation of 15-hydroxyl group Hansen_HS . | |
15-Keto-prostaglandin E2 is further metabolized by its Delta 13-reduction, beta -oxidation and omega oxidation. The ultimate metabolite is (7 alpha -hydroxy-5,11-diketotetranorprosta-1,16-dioic acid) and excreted in urine Hamberg_M et al.. | |
It is well known that the biological activities of various prostaglandins are reduced upon their dehydrogenation at carbon-15 by the catalysis of 15-hydroxyprostaglandin dehydrogenase Anggard_E . | |
cDNA for placental 15-hydroxyprostaglandin dehydrogenase was cloned Ensor_CM et al.. | |
Spectral Information | |
Mass Spectra | DIMETHOXIME TMS ETHER METHYL ESTER ; m/z 494(M+), 479, 463, 404, 373, 321, 180 Morrison_AR et al. |
UV Spectra | METHYL ESTER ; λ MeOH max = 227nm ( ε ∼ 9000) Morrison_AR et al. |
IR Spectra | |
NMR Spectra | |
Other Spectra | |
Chromatograms |
Reported Metabolites, References | ||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|